Người sử dụng ma túy tiêm chích và việc cung cấp các dịch vụ liên quan đến viêm gan C trong một mẫu quốc gia về các chương trình điều trị ma túy

Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) and infection and HCV-related chronic disease.MMWR Morbidity and Mortality Weekly Report. 1998;47:1–39. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.New England Journal of Medicine. 1999;341(8):556–562. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998;18:S6-S10. Williams I. Epidemiology of hepatitis C in the United States.American Journal of Medicine. 1999;107(6B):2S-9S. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications.Journal of Addictive Diseases. 2001;20:19–31. Lorvick J, Kral AH, Seal K, et al. Prevalence and duration of hepatitis C among injection drug users in San Francisco, California.American Journal of Public Health. 2001;91:46–47. Tenant F, Moll D. Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts.Journal of Addictive Diseases. 1995;1463:35–49. Alter MJ. Hepatitis C virus infection in the United States.Journal of Hepatology. 1999;31:88S-91S. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C.Annals of Internal Medicine. 2000;132:296–305. Zweben J. Hepatitis C: education and counseling issues.Journal of Addictive Diseases. 2001;20:33–42. Friedmann PD, Alexander JA, D'Aunno TA. Organizational correlates of access to primary care and mental health services in drug abuse treatment units.Journal of Substance Abuse Treatment. 1999;16(1):71–80. Grella CE, Etheridge RM, Joshi V, et al. Delivery of HIV risk-reduction services in drug treatment programs.Journal of Substance Abuse Treatment. 2000;19:229–237. D'Aunno T, Vaughn TE, McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units.Journal of Health and Social Behavior. 1999;40:175–192. Des Jarlais DC, Schuchat A. Hepatitis C among drug users: deja vu all over again?American Journal of Public Health. 2001;91(1):21–22. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users.Mount Sinai Journal of Medicine. 2000;67:423–428. Watters JK. Impact of HIV risk and infection and the role of preventive services.Journal of Substance Abuse Treatment. 1996;13:375–385. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review.Drug and Alcohol Dependence. 2000;59:17–31. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention.Public Health Reports. 1998;113(1):97–106. Strauss SM, Falkin GP, Vassilev Z, et al. A nationwide survey of hepatitis C services provided by drug treatment programs.Journal of Substance Abuse Treatment. 2002;22:55–62. Price RH. What we know and what we actually do: best practices and their prevalence in substance abuse treatment. In: JA Egertson, DM Fox, AI Leshner, eds.Treating Drug Abusers Effectively. Malden, Mass: Blackwell; 1997:125–155. Paredes A, Zweben J. The hepatitis C epidemic, shall we remain silent?Journal of Addictive Diseases. 2001;20(1):1–7. Astone JM, Strauss SM, Vassilev ZP, et al. Provision of hepatitis C education in a nationwide sample of drug treatment programs.Journal of Drug Education. 2003;33(1):107–117. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.Drug and Alcohol Dependence. 2001;61(3):211–215. Etheridge RM, Hubbard RL, Anderson J, et al. Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS).Psychology of Addictive Behaviors. 1997;11:244–260.